page-title

“Differentiating the Effects of Down Syndrome and Alzheimer’s Disease upon Neuronal Function and Brain Volume”

Chicago, IL – ADM Diagnostics (ADMdx), a company that provides centralized imaging clinical trial services for Alzheimer’s disease and other CNS indications, presented their work in “Differentiating the Effects of Down Syndrome and Alzheimer’s Disease upon Neuronal Function and Brain Volume” at the 2015 Clinical Trials in Alzheimer’s Disease (CTAD) conference. In this work, performed in collaboration with researchers at the University of California San Diego, ADMdx was able to identify brain effects due to emerging Alzheimer’s disease (AD) versus effects due to Down Syndrome (DS), using brain imaging.

Adults with Down Syndrome develop AD and dementia at an accelerated rate, with nearly all Down Syndrome adults in their 40’s having amyloid pathology characteristic of AD. Because of this high rate of disease development, pharmaceutical companies have expressed interest in being able to test AD-targeted drugs in DS adults, particularly before symptoms of dementia appear. However, detecting the degree to which someone is developing damage to AD, and measuring possible drug effects, are difficult due to the cognitive challenges already posed by DS, and the subtlety of early AD symptoms. ADMdx applied proprietary pattern recognition software to the brain images of Down Syndrome patients from UCSD’s study and was able to identify those patients who were developing AD, and quantify the extent to which they were experiencing AD-specific brain decline. ADMdx was able to achieve this using FDG PET scans, which measure brain function associated with glucose metabolism, and separately, with magnetic resonance imaging (MRI) scans, which measure brain structure.

“Our analysis software enables us to separate, within the same person’s brain image, effects due to different factors, allowing selection of patients for clinical trials and measurement of drug effect specific to the target disease” explained Dawn Matthews, CEO of ADMdx. “This analysis, for the first time, clearly showed participants with Down Syndrome exhibited regions of change that can be dissociated into a Downs-specific pattern and an AD-like pattern, and that we can achieve this using both PET and MRI. ”

Michael Rafii MD PhD of the University of California San Diego School of Medicine was Principal Investigator of the ongoing Down Syndrome Biomarker Initiative study, which has been sponsored by Janssen Research and Development. ADMdx’ work was presented at the CTAD conference in Barcelona, Spain on the 6th of November, 2015.

For more information concerning this release please contact Craig Pennington at cpennington@admdx.com or at 314-299-4148. To download a copy of the poster CTAD 2015 Down syndrome final.

Additional Information on the Poster Presentation:

Differentiating the Effects of Down Syndrome and Alzheimer’s Disease upon Neuronal Function and Brain Volume
Dawn Matthews, MS MBA1, Ana Lukic, PhD1, Randolph Andrews, MS1, Boris Marendic, PhD1, James Brewer, PhD2, Lisa Mosconi, PhD3, Stephen Strother, PhD1,4, Miles Wernick, PhD1,5, Mark Schmidt, MD6, Michael Rafii, MD PhD2, for the Alzheimer’s Disease Neuroimaging Initiative

(1)ADM Diagnostics, Chicago, Illinois, USA; (2) University of California San Diego School of Medicine, San Diego, California, USA; (3) New York University, New York, USA; (4) Baycrest Hospital, Toronto, ON, Canada; (5) Illinois Institute of Technology, Chicago, Illinois, USA; (6) Janssen Research and Development, Beerse, Belgium

About ADM Diagnostics

ADM Diagnostics (ADMdx) is a centralized imaging core lab and diagnostic service provider that combines proprietary analysis technology, automated software with complete audit trail, and Central Nervous Systems (CNS) expertise to provide critical insights through advanced image analysis. ADMdx also has an extensive well characterized, in-house database of numerous longitudinal cognitive endpoints, biomarker data, and processed image data that enables it to provide information for clinical trial planning and statistical powering. Specializing in PET (FDG, amyloid, tau) and functional MRI, ADMdx can help pharmaceutical, biopharmaceutical, contract research organizations and academic core labs in:
• Appropriate patient selection
• Prediction of patient clinical trajectory
• Detection and interpretation of drug effect
• Minimizing the required number of subjects
• Planning and statistical powering of clinical trials

In addition, ADMdx is developing diagnostic services and products to improve the early, accurate diagnosis of Alzheimer’s Disease, other dementias, and other brain disorders.

About Clinical Trials in Alzheimer’s Disease (CTAD) Conference

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, predict progression, and assess the effectiveness of new treatments.
The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2014 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD. Again in 2015 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve known and unknown risks and uncertainties that could cause future results or performance to differ materially from those expressed or implied in such statements. These forward-looking statements can be identified by words such as ‘supports’, ‘can’, ‘may be used’, and other similar expressions regarding the performance characteristics of ADM Diagnostics’ (ADMdx’) technology. Any future release of ADMdx’ technology for image analysis is subject to ongoing evaluation by ADMdx and its customers.